Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from in vitro assays.
Saved in:
| Title: | Blinatumomab-driven T-cell activation in αβ and γδ T-cell subsets: insights from in vitro assays. |
|---|---|
| Authors: | Kelm M; Medical Department II, Hematology and Oncology, Christian-Albrechts University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany., Nasr N; Institute of Immunology, Christian-Albrechts University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany., Bendig S; Medical Department II, Hematology and Oncology, Christian-Albrechts University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit Towards a Cure for Adults and Children with Acute Lymphoblastic Leukemia (CATCH ALL) (KFO 5010), Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany., Kabelitz D; Institute of Immunology, Christian-Albrechts University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany., Lustig M; Clinical Research Unit Towards a Cure for Adults and Children with Acute Lymphoblastic Leukemia (CATCH ALL) (KFO 5010), Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Medical Department II, Division of Stem Cell Transplantation and Cellular Immunotherapies, University Hospital Schleswig-Holstein and Christian-Albrechts-University of Kiel, Kiel, Germany., Trautmann H; Medical Department II, Hematology and Oncology, Christian-Albrechts University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany., Laqua A; Medical Department II, Hematology and Oncology, Christian-Albrechts University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany., Peters C; Institute of Immunology, Christian-Albrechts University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany., Wesch D; Institute of Immunology, Christian-Albrechts University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany., Oberg HH; Institute of Immunology, Christian-Albrechts University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany., Janssen O; Institute of Immunology, Christian-Albrechts University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany., Valerius T; Clinical Research Unit Towards a Cure for Adults and Children with Acute Lymphoblastic Leukemia (CATCH ALL) (KFO 5010), Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany.; Medical Department II, Division of Stem Cell Transplantation and Cellular Immunotherapies, University Hospital Schleswig-Holstein and Christian-Albrechts-University of Kiel, Kiel, Germany., Baldus CD; Medical Department II, Hematology and Oncology, Christian-Albrechts University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit Towards a Cure for Adults and Children with Acute Lymphoblastic Leukemia (CATCH ALL) (KFO 5010), Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany., Scheffold A; Institute of Immunology, Christian-Albrechts University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit Towards a Cure for Adults and Children with Acute Lymphoblastic Leukemia (CATCH ALL) (KFO 5010), Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Kiel, Germany.; Technische Universität Berlin, Institute for Biotechnology, Berlin, Germany., Brüggemann M; Medical Department II, Hematology and Oncology, Christian-Albrechts University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit Towards a Cure for Adults and Children with Acute Lymphoblastic Leukemia (CATCH ALL) (KFO 5010), Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany., Chitadze G; Medical Department II, Hematology and Oncology, Christian-Albrechts University of Kiel and University Hospital Schleswig-Holstein, Kiel, Germany.; Clinical Research Unit Towards a Cure for Adults and Children with Acute Lymphoblastic Leukemia (CATCH ALL) (KFO 5010), Funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), Kiel, Germany.; University Cancer Center Schleswig-Holstein (UCCSH), University Hospital Schleswig-Holstein, Kiel, Germany. |
| Source: | Frontiers in immunology [Front Immunol] 2026 Feb 06; Vol. 17, pp. 1739493. Date of Electronic Publication: 2026 Feb 06 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2026.1739493 |